Wolman disease

Results: 19



#Item
11SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Di

SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Di

Add to Reading List

Source URL: www.synageva.com

Language: English - Date: 2014-10-09 07:26:12
12SYNAGEVA BIOPHARMA™ ANNOUNCES SATELLITE SYMPOSIUM AT THE NATIONAL LIPID ASSOCIATION MEETING LEXINGTON, Mass., May 2, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing the

SYNAGEVA BIOPHARMA™ ANNOUNCES SATELLITE SYMPOSIUM AT THE NATIONAL LIPID ASSOCIATION MEETING LEXINGTON, Mass., May 2, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing the

Add to Reading List

Source URL: www.synageva.com

Language: English - Date: 2014-05-02 07:29:47
13LAL DEFICIENCY DISEASE REVIEW PUBLISHED IN ATHEROSCLEROSIS  LEXINGTON, Mass., April 21, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare dise

LAL DEFICIENCY DISEASE REVIEW PUBLISHED IN ATHEROSCLEROSIS LEXINGTON, Mass., April 21, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare dise

Add to Reading List

Source URL: www.synageva.com

Language: English - Date: 2014-04-21 08:00:38
14SYNAGEVA’S SEBELIPASE ALFA RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR EARLY ONSET LAL DEFICIENCY FROM THE U.S. FOOD AND DRUG ADMINISTRATION LEXINGTON, Mass., May 20, [removed]Synageva BioPharma Corp. (Synageva) (NASD

SYNAGEVA’S SEBELIPASE ALFA RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR EARLY ONSET LAL DEFICIENCY FROM THE U.S. FOOD AND DRUG ADMINISTRATION LEXINGTON, Mass., May 20, [removed]Synageva BioPharma Corp. (Synageva) (NASD

Add to Reading List

Source URL: www.synageva.com

Language: English - Date: 2013-05-20 07:13:10
15SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA AT THE NASPGHAN MEETING  LEXINGTON, Mass., October 11, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare

SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA AT THE NASPGHAN MEETING LEXINGTON, Mass., October 11, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare

Add to Reading List

Source URL: www.synageva.com

Language: English - Date: 2013-10-11 07:24:04
16SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA PRESENTATIONS AND SATELLITE SYMPOSIUM AT THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONGRESS LEXINGTON, Mass., June 3, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharm

SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA PRESENTATIONS AND SATELLITE SYMPOSIUM AT THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONGRESS LEXINGTON, Mass., June 3, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharm

Add to Reading List

Source URL: www.synageva.com

Language: English - Date: 2014-06-03 10:39:51
17Chair Rohit Kohli, MBBS, MS Associate Professor of Pediatrics Medical Director, Complex Surgery and Transplant Inpatient Unit Co-Director, Steatohepatitis Center

Chair Rohit Kohli, MBBS, MS Associate Professor of Pediatrics Medical Director, Complex Surgery and Transplant Inpatient Unit Co-Director, Steatohepatitis Center

Add to Reading List

Source URL: www.naspghan.org

Language: English - Date: 2014-06-18 09:22:16
18The people. Their lives. The impact[removed]Annual Report Dear Fellow Shareholders, 2013 was an amazing year for both Synageva and for patients. We met,

The people. Their lives. The impact[removed]Annual Report Dear Fellow Shareholders, 2013 was an amazing year for both Synageva and for patients. We met,

Add to Reading List

Source URL: www.synageva.com

Language: English - Date: 2014-04-23 16:54:16
19Chair Rohit Kohli, MBBS, MS Associate Professor of Pediatrics Medical Director, Complex Surgery and Transplant Inpatient Unit Co-Director, Steatohepatitis Center

Chair Rohit Kohli, MBBS, MS Associate Professor of Pediatrics Medical Director, Complex Surgery and Transplant Inpatient Unit Co-Director, Steatohepatitis Center

Add to Reading List

Source URL: www.naspghan.org

Language: English - Date: 2014-06-27 11:01:50